<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868712</url>
  </required_header>
  <id_info>
    <org_study_id>WU# 04-12020</org_study_id>
    <nct_id>NCT00868712</nct_id>
  </id_info>
  <brief_title>Warfarin and Coronary Calcification Project</brief_title>
  <acronym>WACC</acronym>
  <official_title>Warfarin and Coronary Calcification Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess whether the use of warfarin, a commonly used
      anticoagulation drug, is associated with increased amounts of coronary artery calcification.
      Studies in animals and preliminary but small retrospective studies in humans have suggested a
      possible link to increased tissue calcification with use of this drug. The researchers will
      investigate this by assessing the amount of calcification seen in the coronary arteries using
      a specialized computed tomography (CT) scan (electron-beam CT) and assessing to see if the
      amount is influenced by the amount of time a patient has been taking warfarin. The
      researchers will exclude patients with known coronary artery disease, chronic kidney disease
      or hyperparathyroidism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular Risk Factors to Include the Framingham Risk Score</measure>
    <time_frame>EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: &lt;6 months; 6-24 months; &gt;24 mos.</time_frame>
    <description>The Agatston score is calculated using a non-contrast computed tomography (CT) scan to measure for the presence and severity of coronary artery disease through identification of calcification in the coronary arteries. Scores can range from 0 to several thousands. The measure is without units. Score categories are as follows: 0 = no coronary disease; 1-100 = low amount of coronary artery disease; 101-400 = moderately elevated score / moderate coronary artery disease; 401-1000 = severely elevated score; &gt;1000 very severely elevated score. Higher Agatston scores corelate with more coronary artery disease and predict a higher risk of coronary heart disease events and mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio</measure>
    <time_frame>EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: &lt;6 months; 6-24 months; &gt;24 mos.</time_frame>
    <description>The International Normalized Ratio (INR) is a standardized lab value that measures the intensity of anticogulation using warfarin. It is used to monitor patients taking warfarin.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Coronary Calcification</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Warfarin use &lt; 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Warfarin use 6-24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Warfarin use &gt;24 months</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients without known coronary heart disease, disorders of calcium metabolism or chronic
        kidney disease aged &gt; 18 years who are referred to take or currently taking warfarin and
        are followed in the Anticoagulation Management Clinic at Walter Reed Army Medical Center
        (WRAMC).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years of age or older

          -  Patients referred to begin or already treated with warfarin anticoagulation therapy.

        Exclusion Criteria:

          -  Known prior myocardial infarction or coronary heart disease

          -  History of advanced chronic kidney disease manifested by serum creatinine&gt;2 or
             calculated glomerular filtration rate (GFR)&lt;30

          -  History of hyperparathyroidism

          -  Current hypercalcemia

          -  Current hyperphosphatemia

          -  Uncertain duration of warfarin therapy

          -  Lack of records documenting international normalized ratio (INR) during therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19847375</url>
    <description>Publication abstract</description>
  </link>
  <results_reference>
    <citation>Villines TC, O'Malley PG, Feuerstein IM, Thomas S, Taylor AJ. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study. Calcif Tissue Int. 2009 Dec;85(6):494-500. doi: 10.1007/s00223-009-9300-4. Epub 2009 Oct 22.</citation>
    <PMID>19847375</PMID>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>February 2, 2010</results_first_submitted>
  <results_first_submitted_qc>August 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2012</results_first_posted>
  <last_update_submitted>August 23, 2012</last_update_submitted>
  <last_update_submitted_qc>August 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Walter Reed Army Medical Center</investigator_affiliation>
    <investigator_full_name>Todd C. Villines</investigator_full_name>
    <investigator_title>Director, Cardiovascular Research</investigator_title>
  </responsible_party>
  <keyword>coronary calcification</keyword>
  <keyword>vitamin K dependent proteins</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment is complete. All patients were recruited from within the Walter Reed Anticoagulation Clinic, as specified in the protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Warfarin Use Short Duration</title>
          <description>Warfarin use for less than 6 months</description>
        </group>
        <group group_id="P2">
          <title>2 - Warfarin Use Intermediate</title>
          <description>Warfarin use for 6 to 24 months in duration</description>
        </group>
        <group group_id="P3">
          <title>3 - Warfarin Use Chronic</title>
          <description>Warfarin use &gt;24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Warfarin Use Short Duration</title>
          <description>Warfarin use for less than 6 months</description>
        </group>
        <group group_id="B2">
          <title>2 - Warfarin Use Intermediate</title>
          <description>Warfarin use for 6 to 24 months in duration</description>
        </group>
        <group group_id="B3">
          <title>3 - Warfarin Use Chronic</title>
          <description>Warfarin use &gt;24 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="13"/>
                    <measurement group_id="B2" value="68" spread="11"/>
                    <measurement group_id="B3" value="73" spread="12"/>
                    <measurement group_id="B4" value="68" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular Risk Factors to Include the Framingham Risk Score</title>
        <description>The Agatston score is calculated using a non-contrast computed tomography (CT) scan to measure for the presence and severity of coronary artery disease through identification of calcification in the coronary arteries. Scores can range from 0 to several thousands. The measure is without units. Score categories are as follows: 0 = no coronary disease; 1-100 = low amount of coronary artery disease; 101-400 = moderately elevated score / moderate coronary artery disease; 401-1000 = severely elevated score; &gt;1000 very severely elevated score. Higher Agatston scores corelate with more coronary artery disease and predict a higher risk of coronary heart disease events and mortality.</description>
        <time_frame>EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: &lt;6 months; 6-24 months; &gt;24 mos.</time_frame>
        <population>After interim analysis following n=70 showed no effect, further enrollment was halted.</population>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Use Short Duration</title>
            <description>Warfarin use for less than 6 months</description>
          </group>
          <group group_id="O2">
            <title>2 - Warfarin Use Intermediate</title>
            <description>Warfarin use for 6 to 24 months in duration</description>
          </group>
          <group group_id="O3">
            <title>3 - Warfarin Use Chronic</title>
            <description>Warfarin use &gt;24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular Risk Factors to Include the Framingham Risk Score</title>
          <description>The Agatston score is calculated using a non-contrast computed tomography (CT) scan to measure for the presence and severity of coronary artery disease through identification of calcification in the coronary arteries. Scores can range from 0 to several thousands. The measure is without units. Score categories are as follows: 0 = no coronary disease; 1-100 = low amount of coronary artery disease; 101-400 = moderately elevated score / moderate coronary artery disease; 401-1000 = severely elevated score; &gt;1000 very severely elevated score. Higher Agatston scores corelate with more coronary artery disease and predict a higher risk of coronary heart disease events and mortality.</description>
          <population>After interim analysis following n=70 showed no effect, further enrollment was halted.</population>
          <units>Agatston Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" spread="285"/>
                    <measurement group_id="O2" value="289" spread="382"/>
                    <measurement group_id="O3" value="426" spread="789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>International Normalized Ratio</title>
        <description>The International Normalized Ratio (INR) is a standardized lab value that measures the intensity of anticogulation using warfarin. It is used to monitor patients taking warfarin.</description>
        <time_frame>EBCT scan is done at time of enrollment of patient into 1 of 3 groups based on warfarin use duration: &lt;6 months; 6-24 months; &gt;24 mos.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Warfarin Use Short Duration</title>
            <description>Warfarin use for less than 6 months</description>
          </group>
          <group group_id="O2">
            <title>2 - Warfarin Use Intermediate</title>
            <description>Warfarin use for 6 to 24 months in duration</description>
          </group>
          <group group_id="O3">
            <title>3 - Warfarin Use Chronic</title>
            <description>Warfarin use &gt;24 months</description>
          </group>
        </group_list>
        <measure>
          <title>International Normalized Ratio</title>
          <description>The International Normalized Ratio (INR) is a standardized lab value that measures the intensity of anticogulation using warfarin. It is used to monitor patients taking warfarin.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.9"/>
                    <measurement group_id="O2" value="2.4" spread="0.4"/>
                    <measurement group_id="O3" value="2.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month (until calcium scan completed).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Warfarin Use Short Duration</title>
          <description>Warfarin use for less than 6 months</description>
        </group>
        <group group_id="E2">
          <title>2 - Warfarin Use Intermediate</title>
          <description>Warfarin use for 6 to 24 months in duration</description>
        </group>
        <group group_id="E3">
          <title>3 - Warfarin Use Chronic</title>
          <description>Warfarin use &gt;24 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Cross-sectional nature, small sample size. Initially powered for sample size of 100 subjects, our trial was stopped early after an interim analysis at 70 subjects demonstrated no trend for effect of warfarin after adjusting for standard risk factors.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Todd C. Villines, MD</name_or_title>
      <organization>Walter Reed Army Medical Center, Cardiology Service</organization>
      <phone>301-295-7839</phone>
      <email>todd.villines@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

